Literature DB >> 19262583

Independent association of circulating resistin with glomerular filtration rate in the early stages of essential hypertension.

K Dimitriadis1, C Tsioufis, M Selima, D Tsiachris, A Miliou, A Kasiakogias, E Andrikou, D Tousoulis, C Stefanadis.   

Abstract

Resistin, a newly discovered protein, promotes endothelial dysfunction and proinflammatory activation, contributing to subclinical atherosclerosis in different clinical settings. In this study we sought to investigate the relationship of increased resistin levels with estimated glomerular filtration rate (eGFR), the most established marker of kidney impairment, in hypertensive subjects. Our population consisted of 132 untreated non-diabetic subjects with stage I-II essential hypertension (49 males, mean age=54 years, office blood pressure (BP)=159/100 mm Hg). In all patients eGFR was assessed by the Modification in Renal Disease equation and venous blood sampling was performed for estimation of resistin concentrations. The distribution of resistin was split by the median (4.63 ng ml(-1)) and accordingly subjects were stratified into those with high and low values. Hypertensive patients with high (n=66) compared to those with low resistin (n=66) exhibited lower eGFR values (77.1+/-9.4 vs 89.1+/-12.2 ml min(-1) per 1.73m(2), P<0.0001), even after adjustment for established confounders. In the total population, resistin was associated with 24-h systolic BP (r=0.244, P<0.05), serum creatinine (r=0.311, P=0.007) and eGFR (r=-0.519, P<0.0001). Multiple regression analysis revealed that age (b=0.379, P=0.01), body mass index (b=0.158, P=0.022), 24-h systolic BP (b=0.284, P=0.006) and resistin (b=0.429, P<0.0001) were independent predictors of eGFR (R(2)=0.436, P<0.0001). In essential hypertensive subjects, higher resistin levels are associated with renal function impairment, as reflected by decreased eGFR. Moreover, the independent association of resistin with eGFR suggests involvement of resistin in the progression of kidney damage in the early stages of hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19262583     DOI: 10.1038/jhh.2009.12

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  10 in total

1.  Plasma resistin levels associate with risk for hypertension among nondiabetic women.

Authors:  Luxia Zhang; Gary C Curhan; John P Forman
Journal:  J Am Soc Nephrol       Date:  2010-04-08       Impact factor: 10.121

2.  Plasma levels of resistin-like molecule beta in humans.

Authors:  Andrew P Neilson; Zora Djuric; Susan Land; Ikuko Kato
Journal:  Cancer Epidemiol       Date:  2010-11-19       Impact factor: 2.984

3.  The association of plasma resistin with dietary sodium manipulation, the renin-angiotensin-aldosterone system, and 25-hydroxyvitamin D3 in human hypertension.

Authors:  Anand Vaidya; Luminita Pojoga; Patricia C Underwood; John P Forman; Paul N Hopkins; Gordon H Williams; Jonathan S Williams
Journal:  Clin Endocrinol (Oxf)       Date:  2011-03       Impact factor: 3.478

4.  Resistin as a potential marker of renal disease in lupus nephritis.

Authors:  J Hutcheson; Y Ye; J Han; C Arriens; R Saxena; Q-Z Li; C Mohan; T Wu
Journal:  Clin Exp Immunol       Date:  2015-03       Impact factor: 4.330

5.  Aldehyde dehydrogenase 2 as a potential protective factor for renal insufficiency in Japanese subjects with heart failure: a pilot study.

Authors:  K Morita; K Oniki; H Miyazaki; J Saruwatari; Y Ogata; M Mizobe; M Yamamuro; S Hokimoto; H Ogawa; K Nakagawa
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

6.  Preclinical cardiorenal interrelationships in essential hypertension.

Authors:  Costas Tsioufis; Dimitrios Tsiachris; Alexandros Kasiakogias; Kyriakos Dimitriadis; Dimitris Petras; Dimitris Goumenos; Konstantinos Siamopoulos; Christodoulos Stefanadis
Journal:  Cardiorenal Med       Date:  2013-04       Impact factor: 2.041

7.  Serum resistin and glomerular filtration rate in patients with type 2 diabetes.

Authors:  Lorena Ortega Moreno; Lucia Salvemini; Christine Mendonca; Massimiliano Copetti; Concetta De Bonis; Salvatore De Cosmo; Alessandro Doria; Vincenzo Trischitta; Claudia Menzaghi
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

Review 8.  Resistin, an Adipokine with Non-Generalized Actions on Sympathetic Nerve Activity.

Authors:  Emilio Badoer; Samin Kosari; Martin J Stebbing
Journal:  Front Physiol       Date:  2015-11-10       Impact factor: 4.566

Review 9.  The complex effects of adipokines in the patients with kidney disease.

Authors:  Sahar Vahdat
Journal:  J Res Med Sci       Date:  2018-07-26       Impact factor: 1.852

10.  Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus.

Authors:  Akio Nakashima; Keitaro Yokoyama; Daiji Kawanami; Ichiro Ohkido; Mitsuyoshi Urashima; Kazunori Utsunomiya; Takashi Yokoo
Journal:  Sci Rep       Date:  2018-09-18       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.